In October 2015 InfraReDx Inc was acquired by Nipro Corporation - a firm with which the smaller firm had been collaborating. The firm had previously filed in late 2014 for IPO; and then postponed that arrangement. InfraReDx, Inc. is medical device company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. The firm is develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated by enabling true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. The TVC system is approved for use in the United States, Europe, and Japan.
